{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02883595",
      "orgStudyIdInfo": {
        "id": "thymosin alpha 1"
      },
      "organization": {
        "fullName": "Sun Yat-sen University",
        "class": "OTHER"
      },
      "briefTitle": "Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis",
      "officialTitle": "Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis"
    },
    "statusModule": {
      "statusVerifiedDate": "2019-04",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2016-03-31",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2016-09-30",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2016-12-31",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2016-08-10",
      "studyFirstSubmitQcDate": "2016-08-24",
      "studyFirstPostDateStruct": {
        "date": "2016-08-30",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2019-04-02",
      "lastUpdatePostDateStruct": {
        "date": "2019-04-04",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Wu Jianfeng",
        "investigatorTitle": "Clinical Professor",
        "investigatorAffiliation": "Sun Yat-sen University"
      },
      "leadSponsor": {
        "name": "Sun Yat-sen University",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to determine whether thymosin alpha 1 is effective on improving monocyte function and has the desired pharmacologic activity for sepsis",
      "detailedDescription": "Part 1: To observe the function of thymosin alpha 1 in sepsis patients via improving phagocytosis, bacteria eradication and antigen-presenting on monocyte Part 2: Pharmacokinetics of thymosin alpha 1 for sepsis"
    },
    "conditionsModule": {
      "conditions": [
        "Sepsis"
      ],
      "keywords": [
        "thymosin alpha 1; sepsis; monocyte; pharmacokinetics"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 20,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "thymosin alpha 1",
          "type": "EXPERIMENTAL",
          "description": "Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.",
          "interventionNames": [
            "Drug: thymosin alpha 1"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Subcutaneous injections of placebo (saline) twice per day for seven days",
          "interventionNames": [
            "Other: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "thymosin alpha 1",
          "description": "Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.",
          "armGroupLabels": [
            "thymosin alpha 1"
          ],
          "otherNames": [
            "thymalfasin"
          ]
        },
        {
          "type": "OTHER",
          "name": "Placebo",
          "description": "Subcutaneous injections of placebo (saline) twice per day for seven days",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Ta 1 improving immune function of monocyte for sepsis, used by flow cytometric to measure phagocytosis(CD11b, CD64), antigen presenting(HLA-DR, CD86 and PD-L1), and apoptosis(active caspase 3) on monocyte,",
          "description": "Phagocytosis was measured by expression of monocyte surface antigen CD64 and CD11b, as well as pHrodo™ BioParticles® Phagocytosis Kits to assessing phagocytic activity on monocyte; antigen presenting was measured by HLA-DR, costimulatory molecule CD86 and inhibitory molecule PD-L1 on monocyte; apoptosis was measured by active caspase 3 on monocyte",
          "timeFrame": "28days"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Relationship between concentration of Ta 1 and prognosis of sepsis patients, measured by concentration of Ta 1, 28-day all-cause mortality, 28-day clearance rate of pathogenic microorganism, ICU stays and hospital stays",
          "description": "Concentration of Ta 1 was measured on day 0, 3 and 7 after injection drug or placebo",
          "timeFrame": "28 days"
        },
        {
          "measure": "Maximum observed serum concentration (Cmax) of Ta 1",
          "timeFrame": "7 days"
        },
        {
          "measure": "Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Ta 1",
          "timeFrame": "7 days"
        },
        {
          "measure": "Terminal serum half-life (T-HALF) of Ta 1",
          "timeFrame": "7 days"
        },
        {
          "measure": "Time of maximum observed serum concentration (Tmax) of Ta 1",
          "timeFrame": "7 days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Written informed consent from the patients or their next of kin for patients unable to consent\n2. Age ≥18 yrs\n3. Presence of sepsis/ septic shock according to sepsis 3.0\n\nExclusion Criteria:\n\n1. Pregnant or lactation period.\n2. Age \\<18 yrs\n3. Receiving immunosuppressive therapy such as cyclosporine, azathioprine or cancer chemotherapy within one month.\n4. History of bone marrow, lung, liver, kidney, pancreas or small bowel transplantation;\n5. Acute pancreatitis with no established source of infection.\n6. Not expected to survive 28 days because of end-stage diseases.\n7. Participation in another clinical trial.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Wu Jianfeng, M. D",
          "affiliation": "First Affiliated Hospital, Sun Yat-Sen University",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Sun Yat-sen University",
          "city": "Guangzhou",
          "state": "Guangdong",
          "zip": "510080",
          "country": "China",
          "geoPoint": {
            "lat": 23.11667,
            "lon": 113.25
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "UNDECIDED"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-11"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D018805",
          "term": "Sepsis"
        }
      ],
      "ancestors": [
        {
          "id": "D007239",
          "term": "Infections"
        },
        {
          "id": "D018746",
          "term": "Systemic Inflammatory Response Syndrome"
        },
        {
          "id": "D007249",
          "term": "Inflammation"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000077596",
          "term": "Thymalfasin"
        }
      ],
      "ancestors": [
        {
          "id": "D013947",
          "term": "Thymosin"
        },
        {
          "id": "D013951",
          "term": "Thymus Hormones"
        },
        {
          "id": "D006728",
          "term": "Hormones"
        },
        {
          "id": "D006730",
          "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
        },
        {
          "id": "D036361",
          "term": "Peptide Hormones"
        },
        {
          "id": "D010455",
          "term": "Peptides"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        }
      ]
    }
  },
  "hasResults": false
}